February 16, 2018 / 3:43 PM / 6 months ago

BRIEF-UCB To Present Phase 2b Findings For Bimekizumab

Feb 16 (Reuters) - Ucb Sa:

* UCB ADVANCES PSORIASIS PIPELINE WITH POSITIVE DATA AT AMERICAN ACADEMY OF DERMATOLOGY ANNUAL MEETING (AAD 2018)

* FULL EFFICACY AND SAFETY FINDINGS FROM PHASE 2B BE ABLE STUDY ON INVESTIGATIONAL MOLECULE BIMEKIZUMAB WILL HIGHLIGHT DUAL NEUTRALIZATION OF IL-17A AND IL-17F Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below